Active Ingredient History
Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist. Losartant is recommended as one of several preferred agents for the initial management of hypertension. Administration of losartan reduces the risk of stroke in patients with hypertension and left ventricular hypertrophy. Losartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Aging (Phase 2)
Albinism, Oculocutaneous (Phase 1/Phase 2)
Alzheimer Disease (Phase 2/Phase 3)
Anemia, Sickle Cell (Phase 2)
Aortic Coarctation (Phase 3)
Aortic Valve Insufficiency (Phase 4)
Aortic Valve Stenosis (Phase 4)
Apnea (Phase 4)
Arthroplasty, Replacement, Knee (Phase 1/Phase 2)
Ascites (Phase 4)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Bipolar Disorder (Phase 4)
Blood Pressure (Phase 4)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Bronchitis, Chronic (Phase 4)
Cardiac Output, Low (Phase 4)
Cardiomyopathy, Hypertrophic (Phase 2)
Carotid Stenosis (Phase 4)
Cartilage Diseases (Phase 1/Phase 2)
Cerebral Small Vessel Diseases (Phase 3)
Child (Phase 1/Phase 2)
Cognition Disorders (Phase 2/Phase 3)
Colitis, Ulcerative (Phase 4)
Colorectal Neoplasms (Phase 2)
Coronary Artery Disease (Phase 4)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Crohn Disease (Phase 4)
Cystic Fibrosis (Phase 2)
Dementia (Phase 2)
Depressive Disorder, Major (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Drug Interactions (Phase 1)
Drug Therapy (Phase 2)
Dyslipidemias (Phase 3)
Emphysema (Phase 4)
Endomyocardial Fibrosis (Phase 2)
Eosinophilic Esophagitis (Phase 2)
Essential Hypertension (Phase 4)
Exercise (Phase 3)
Fasting (Phase 1)
Fibrosis (Phase 4)
Glioblastoma (Phase 3)
Glomerulonephritis (Phase 4)
Glomerulonephritis, IGA (Phase 4)
Glomerulosclerosis, Focal Segmental (Phase 2)
Glucose Intolerance (Phase 4)
Graft Rejection (Phase 4)
Hamstring Tendons (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 2)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Ventricles (Phase 4)
Hepatitis C, Chronic (Phase 4)
Hermanski-Pudlak Syndrome (Phase 1/Phase 2)
Hip Injuries (Phase 1/Phase 2)
HIV Infections (Phase 4)
Hyperaldosteronism (Phase 4)
Hyperglycemia (Phase 4)
Hyperkalemia (Phase 2)
Hyperlipidemias (Phase 3)
Hyperoxaluria (Phase 3)
Hypertension ()
Hypertension, Pulmonary (Phase 3)
Hypertrophy, Left Ventricular (Phase 4)
Hyperuricemia (Phase 4)
Hypoxia (Phase 4)
Idiopathic Pulmonary Fibrosis (Phase 2/Phase 3)
Inflammation (Phase 3)
Insulin Resistance (Phase 4)
Ischemic Stroke (Phase 4)
Keloid (Phase 1/Phase 2)
Kidney Calculi (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Cirrhosis, Alcoholic (Phase 4)
Liver Transplantation (Phase 4)
Losartan (Phase 4)
Lung Neoplasms (Phase 3)
Macular Edema (Phase 2)
Marfan Syndrome (Phase 3)
Melanoma (Phase 1)
Membranes (Phase 4)
Mental Disorders (Phase 4)
Mental Health (Phase 4)
Metabolic Detoxication, Phase I (Phase 1)
Metabolic Diseases (Phase 3)
Metabolic Syndrome (Phase 4)
Microvascular Angina (Phase 3)
Mucopolysaccharidoses (Phase 2)
Mucopolysaccharidosis IV (Phase 2)
Mucopolysaccharidosis VI (Phase 2)
Multiple Sclerosis (Phase 1/Phase 2)
Multiple System Atrophy (Phase 1)
Neoplasms (Phase 2)
Neuroma, Acoustic (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 3)
Obesity (Phase 4)
Obesity, Morbid (Phase 1/Phase 2)
Osteoarthritis, Hip (Phase 1/Phase 2)
Osteoarthritis, Knee (Phase 1/Phase 2)
Osteosarcoma (Phase 1)
Overweight (Phase 3)
Pancreatic Neoplasms (Phase 2)
Pancreatitis (Phase 1)
Peripheral Arterial Disease (Early Phase 1)
Peritoneal Dialysis (Phase 4)
Pharmacogenetics (Phase 4)
Platelet-Rich Plasma (Phase 4)
Platelet Storage Pool Deficiency (Phase 1/Phase 2)
Porphyria, Acute Intermittent (Phase 1)
Porphyrias (Phase 1)
Postural Orthostatic Tachycardia Syndrome (Early Phase 1)
Prediabetic State (Phase 2)
Pre-Eclampsia (Early Phase 1)
Prehypertension (Phase 2)
Proteinuria (Phase 4)
Psoriasis (Phase 2)
Psychotic Disorders (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Pulmonary Fibrosis (Phase 2/Phase 3)
Pure Autonomic Failure (Phase 1)
Radiation Fibrosis Syndrome (Phase 2)
Renal Insufficiency, Chronic (Phase 3)
Respiratory Distress Syndrome (Phase 2)
Sarcopenia (Phase 2)
Schizophrenia (Phase 4)
Sedentary Behavior (Phase 2)
Severe Acute Respiratory Syndrome (Phase 4)
Sex Characteristics (Early Phase 1)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Smoking (Phase 4)
Sports Medicine (Phase 4)
Sprains and Strains (Phase 4)
Stenosis, Pulmonary Vein (Phase 1/Phase 2)
Stomatitis (Phase 2)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Tetralogy of Fallot (Phase 2)
Tissues (Phase 2)
Vascular Access Devices (Early Phase 1)
Vascular Remodeling (Phase 3)
Ventricular Dysfunction, Left (Phase 3)
Ventricular Dysfunction, Right (Phase 2)
Ventricular Remodeling (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue